Matches in Nanopublications for { ?s ?p "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP718173.RA9HeVwZC2lQw02BeVEFDB8jgTa5PoHLZbOAFHb-d9dSQ130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718173.RA9HeVwZC2lQw02BeVEFDB8jgTa5PoHLZbOAFHb-d9dSQ130_provenance.
- assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998061.RAdbGHXpclRb-9MQ61m6jQJ2fp7JwRHLvLqmTQAT24QZw130_provenance.
- NP786378.RAsQ6vjqtHtgGMlnd6vHVGsLfP19fwQ9SJ5xZqnpbyJSY130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786378.RAsQ6vjqtHtgGMlnd6vHVGsLfP19fwQ9SJ5xZqnpbyJSY130_provenance.
- NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786391.RAls_MBIn_tbWJ0KdEp_R581roQSOWISBG9iGZdscUB6s130_provenance.
- NP998063.RAJPmTLgmTClZEaU4VcwjeFuWoXhX0yaN5yTkgmwXe4Ds130_assertion description "[Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998063.RAJPmTLgmTClZEaU4VcwjeFuWoXhX0yaN5yTkgmwXe4Ds130_provenance.